Literature DB >> 17112963

Therapeutic effects of paclitaxel-containing ultrasound contrast agents.

Michaelann Shortencarier Tartis1, Jennifer McCallan, Aaron F H Lum, Rachel LaBell, Susanne M Stieger, Terry O Matsunaga, Katherine W Ferrara.   

Abstract

Drug delivery vehicles that combine ultrasonic and molecular targeting are shown to locally concentrate a drug in a region-of-interest. The drug delivery vehicles, referred to as acoustically active lipospheres (AALs), are microbubbles surrounded by a shell of oil and lipid. In a region limited to the focal area of ultrasound application, circulating AALs are deflected by radiation force to a vessel wall and can subsequently be fragmented. Ligands targeting the alphavbeta3 integrin are conjugated to the AAL shell and increase in vitro binding by 26.5-fold over nontargeted agents. Toxicity assays demonstrate that paclitaxel-containing AALs exert a greater antiproliferative effect after insonation than free paclitaxel at an equivalent concentration. Lastly, ultrasound and molecular targeting are combined to deliver a model drug to the endothelium and interstitium of chorioallantoic membrane vasculature in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17112963     DOI: 10.1016/j.ultrasmedbio.2006.03.017

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  50 in total

1.  Evaluation of the temporal window for drug delivery following ultrasound-mediated membrane permeability enhancement.

Authors:  Anna Yudina; Matthieu Lepetit-Coiffé; Chrit T W Moonen
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

Review 2.  Leveraging the power of ultrasound for therapeutic design and optimization.

Authors:  Charles F Caskey; Xiaowen Hu; Katherine W Ferrara
Journal:  J Control Release       Date:  2011-07-30       Impact factor: 9.776

Review 3.  Overview of therapeutic ultrasound applications and safety considerations.

Authors:  Douglas L Miller; Nadine B Smith; Michael R Bailey; Gregory J Czarnota; Kullervo Hynynen; Inder Raj S Makin
Journal:  J Ultrasound Med       Date:  2012-04       Impact factor: 2.153

4.  Breakup of finite thickness viscous shell microbubbles by ultrasound: a simplified zero-thickness shell model.

Authors:  Chao-Tsung Hsiao; Georges L Chahine
Journal:  J Acoust Soc Am       Date:  2013-04       Impact factor: 1.840

Review 5.  Phase-shift, stimuli-responsive perfluorocarbon nanodroplets for drug delivery to cancer.

Authors:  Natalya Rapoport
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2012-06-22

6.  Ultrasound-triggered release of recombinant tissue-type plasminogen activator from echogenic liposomes.

Authors:  Denise A B Smith; Sampada S Vaidya; Jonathan A Kopechek; Shao-Ling Huang; Melvin E Klegerman; David D McPherson; Christy K Holland
Journal:  Ultrasound Med Biol       Date:  2010-01       Impact factor: 2.998

7.  Induction of enhanced immunogenic cell death through ultrasound-controlled release of doxorubicin by liposome-microbubble complexes.

Authors:  Feng-Ying Huang; Jing Lei; Yan Sun; Fei Yan; Bin Chen; Liming Zhang; Zhuoxuan Lu; Rong Cao; Ying-Ying Lin; Cai-Chun Wang; Guang-Hong Tan
Journal:  Oncoimmunology       Date:  2018-03-26       Impact factor: 8.110

8.  Assessment of the biodistribution of an [(18) F]FDG-loaded perfluorocarbon double emulsion using dynamic micro-PET in rats.

Authors:  Mario L Fabiilli; Morand R Piert; Robert A Koeppe; Phillip S Sherman; Carole A Quesada; Oliver D Kripfgans
Journal:  Contrast Media Mol Imaging       Date:  2013 Jul-Aug       Impact factor: 3.161

Review 9.  Ultrasound-mediated drug delivery for cardiovascular disease.

Authors:  Jonathan T Sutton; Kevin J Haworth; Gail Pyne-Geithman; Christy K Holland
Journal:  Expert Opin Drug Deliv       Date:  2013-03-01       Impact factor: 6.648

10.  Design and evaluation of doxorubicin-containing microbubbles for ultrasound-triggered doxorubicin delivery: cytotoxicity and mechanisms involved.

Authors:  Ine Lentacker; Bart Geers; Joseph Demeester; Stefaan C De Smedt; Niek N Sanders
Journal:  Mol Ther       Date:  2009-07-21       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.